LYEL Key Statistics, Chart & Performance
The current stock price of LYEL is 24.3 USD. In the past month the price decreased by -16.98%. In the past year, price increased by 101.16%.
LYEL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.72 | 396.12B | ||
| AMGN | AMGEN INC | 15.09 | 177.76B | ||
| GILD | GILEAD SCIENCES INC | 14.73 | 149.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.06 | 119.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.8 | 84.19B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 783.14 | 52.76B | ||
| INSM | INSMED INC | N/A | 36.31B | ||
| NTRA | NATERA INC | N/A | 33.06B | ||
| BIIB | BIOGEN INC | 11.11 | 27.29B | ||
| INCY | INCYTE CORP | 16.5 | 20.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.6 | 21.14B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.76B |
Related stock screener links
About LYEL
Company Profile
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company is headquartered in South San Francisco, California and currently employs 300 full-time employees. The company went IPO on 2021-06-17. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The firm has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Company Info
LYELL IMMUNOPHARMA INC
201 Haskins Way, Suite 301
South San Francisco CALIFORNIA US
CEO: Elizabeth Homans
Employees: 300
Phone: 16506950677
LYELL IMMUNOPHARMA INC / LYEL FAQ
What does LYELL IMMUNOPHARMA INC do?
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company is headquartered in South San Francisco, California and currently employs 300 full-time employees. The company went IPO on 2021-06-17. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The firm has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
What is the current price of LYEL stock?
The current stock price of LYEL is 24.3 USD. The price decreased by -2.99% in the last trading session.
Does LYEL stock pay dividends?
LYEL does not pay a dividend.
How is the ChartMill rating for LYELL IMMUNOPHARMA INC?
LYEL has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of LYEL stock?
LYELL IMMUNOPHARMA INC (LYEL) operates in the Health Care sector and the Biotechnology industry.
Would investing in LYELL IMMUNOPHARMA INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on LYEL.
Can you provide the market cap for LYELL IMMUNOPHARMA INC?
LYELL IMMUNOPHARMA INC (LYEL) has a market capitalization of 515.65M USD. This makes LYEL a Small Cap stock.
LYEL Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to LYEL. When comparing the yearly performance of all stocks, LYEL is one of the better performing stocks in the market, outperforming 95.48% of all stocks.
LYEL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LYEL. LYEL has a great financial health rating, but its profitability evaluates not so good.
LYEL Financial Highlights
Over the last trailing twelve months LYEL reported a non-GAAP Earnings per Share(EPS) of -12.56. The EPS increased by 20.51% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -79.9% | ||
| ROE | -99.09% | ||
| Debt/Equity | 0 |
LYEL Forecast & Estimates
8 analysts have analysed LYEL and the average price target is 30.26 USD. This implies a price increase of 24.53% is expected in the next year compared to the current price of 24.3.
For the next year, analysts expect an EPS growth of 28.6% and a revenue growth 2.27% for LYEL